In this video interview produced in partnership with IBTV, we sit down with John Tomtishen, Global Head of Cell Therapy Field Application Scientists and Strategic Alliances at Catalent, to discuss his career and the changes he has witnessed across the cell therapy field.
Tomtishen explains why developers should prioritize product characterization and CMC early in development, while exploring the technologies and manufacturing strategies that could improve scalability. He also shares his perspective on what the industry must do to bring the next generation of transformative cell therapies to more patients.
Watch the full interview below.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
